Business Wire

SFL: Historically Strong Results for 2017 That Validate the Value Creation Strategy

Del

Regulatory News:

The financial statements for the year ended 31 December 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 9 February 2018 at a meeting chaired by Juan-José Brugera.
Business indicators were very robust, thanks to the high portfolio occupancy rate and growth in rental income, while the year also saw further strong gains in the portfolio’s appraisal value and the Company’s net asset value.
The auditors have completed their audit of the annual financial information and are in the process of issuing their report.

“Our 2017 performance validates our value creation strategy of investing in prime office property in the most attractive districts of Paris and creating a high value for users via an exceptional standard of amenities,” commented Nicolas Reynaud, Chief Executive Officer of SFL.

Consolidated data (€ millions)            
    2017   2016   Change
Rental income   195.8   198.1   -1.2%
Adjusted operating profit* 164.1 169.7 -3.3%
Attributable net profit 685.3 504.1 +35.9%
EPRA earnings   102.4   100.9   +1.5%
* Operating profit before disposal gains and losses and fair value adjustments
             
    31/12/2017   31/12/2016   Change
Attributable equity 3,763 3,123 +20.5%
Consolidated portfolio value excluding transfer costs 6,229 5,736 +8.6%
Consolidated portfolio value including transfer costs   6,619   6,092   +8.7%
EPRA NNNAV 3,729 3,082 +21.0%
EPRA NNNAV per share   €80.1   €66.2  

Results: robust operating profit and growth in net profit driven by an increase in the portfolio value

Rental income amounted to €195.8 million in 2017, down by a modest €2.4 million or 1.2% from the €198.1 million reported in 2016.

  • On a like-for-like basis (excluding all changes in the portfolio affecting year-on-year comparisons), rental income was €6.2 million higher, a 3.6% increase that was attributable to new leases signed in 2016 and 2017, mainly for the Cézanne Saint-Honoré, 9 Percier and 103 Grenelle properties.
  • Changes in assets under redevelopment between the two periods had a €2.6 million negative impact on rental income, with several floors of offices in the Cézanne Saint-Honoré complex and other properties taken off the market for extensive renovation after their tenants moved out.
  • The sale of the IN/OUT building on 29 September 2017 led to €3.3 million decrease in rental income compared with 2016.
  • Lastly, lease termination penalties received from tenants added a net €0.5 million to rental income in 2017 compared with €3.2 million in 2016.

Operating profit before disposal gains and losses and fair value adjustments to investment properties amounted to €164.1 million in 2017 versus €169.7 million in 2016.

The portfolio’s appraisal value grew by 12.6% over the year on a like-for-like basis. The increase led to the recognition of positive fair value adjustments to investment properties of €635.1 million in 2017 (versus €438.0 million in 2016). Profit for the year was also boosted by the €80.3 million gain realised on the sale of the IN/OUT building.

Net finance costs continued to fall sharply, amounting to €40.7 million in 2017 compared with €48.1 million in 2016. Recurring finance costs were down by €4.7 million in 2017, reflecting SFL’s lower average refinancing costs and the reduction in its total debt.

After taking into account these key items, the Group reported attributable net profit for the year of €685.3 million versus €504.1 million in 2016. Excluding the impact of disposals, changes in fair value of investment properties and financial instruments and the related tax effect, EPRA earnings amounted to €102.4 million in 2017 versus €100.9 million the year before (an increase of 1.5%).

Business review: increase in rental income, low vacancy rate, and a pipeline of emblematic projects

Rental operations:
In a growing rental market, shaped by the lowest vacancy rate in the Paris region since 2007, stronger corporate demand and a shortage of available high quality properties, especially in Paris itself, SFL signed a large number of leases in 2017 representing a total surface area of some 21,000 sq.m. Highlights of the year included:

  • Leasing of the entire 2,900 sq.m. of vacant space in the 103 Grenelle property to two tenants, Edouard Denis Développement and Calvin Klein.
  • Leasing of 3,500 sq.m. of offices in the Cézanne Saint-Honoré complex to LEK Consulting and KBL Richelieu.
  • Leasing of 2,800 sq.m. in the Washington Plaza complex to various tenants.
  • Leasing of a 3,400 sq.m. unit in the 92 Champs-Elysées building to WeWork.
  • Leasing of retail space in Galerie des Champs-Elysées for the new concept store opened by l’Occitane and Pierre Hermé in December 2017.

Nominal office rents for leases signed in 2017 averaged €733 per sq.m. with effective rents averaging €629 per sq.m, illustrating SFL’s ability to leverage the quality and scarcity of its products to keep rents high while maintaining a disciplined approach to rental incentives.

The physical occupancy rate for revenue-generating properties at 31 December 2017 was 96.4%, compared with 97.0% at the previous year-end. At 3.1%, the EPRA vacancy rate was stable over the year, further illustrating the outstanding attractiveness of the SFL portfolio and the Group’s ability to maintain full occupancy of its properties.

Portfolio operations:
In January 2017, SFL entered into a €165 million deal to acquire SMA’s historical headquarters building, a 21,000 sq.m. property located at 112-122 avenue Emile Zola in the 15th arrondissement of Paris. SFL acquired title to the property in November 2017 when SMA moved out. The building stands on a 6,300 sq.m. plot featuring a tree-filled garden. It dates back to 1966 and will be completely remodelled.

On 29 September 2017, the IN/OUT building located at 46 Quai Alphonse le Gallo in Boulogne-Billancourt was sold to Primonial REIM. The 35,000 sq.m. building was completely remodelled in a project launched in 2011. Since 2015, it has been leased in full to OECD under a lease expiring in 2027. The building was sold for €445 million excluding transfer costs, generating a capital gain of €80.3 million that was recognised in 2017.

Development operations:
Capital expenditure for 2017 amounted to €32.8 million and mainly concerned the renovation of vacated floors in existing buildings and building redevelopment projects. The development pipeline at 31 December 2017 concerned around 13% of the Group’s portfolio and consisted mainly of three flagship projects that will be deployed over the next four years, as follows:

  • The core of the Louvre Saint-Honoré complex, representing some 15,000 sq.m. of retail space.
  • The office complex on avenue Emile Zola acquired in 2017, which will be completely remodelled to become a major business centre in the heart of the 15th arrondissement of Paris.
  • The 9,000 sq.m. building at 96 avenue d’Iéna, which will be extensively renovated to offer services meeting the very highest standards.

Financing: historically low debt and average borrowing costs

Net debt at 31 December 2017 amounted to €1,631 million (compared with €1,931 million at 31 December 2016), representing a loan-to-value ratio of 24.6%. At 31 December 2017, the average cost of debt after hedging was 1.7% and the average maturity was 4.5 years.

In 2017, the remaining €301 million worth of November 2012 bonds was redeemed and two new 6- and 7-year revolving bank lines of credit totalling €250 million were obtained for general corporate purposes.

At 31 December 2017, SFL had €760 million in undrawn back-up lines of credit that are available to finance investment opportunities and cover the Group’s liquidity risk.

In October 2017, Standard & Poor’s upgraded SFL’s rating to BBB+ with a stable outlook.

Net Asset Value: portfolio value tops €6 billion

The consolidated market value of the portfolio at 31 December 2017 was €6,229 million excluding transfer costs versus €5,736 million at 31 December 2016, representing an increase of 8.6% as reported and 12.6% on a like-for-like basis. This further increase in appraisal values primarily reflects the upward pressure of narrower investment market yields for prime properties and the Group’s improved lease terms.

The average EPRA topped-up net investment yield (NIY) stood at 3.2% at 31 December 2017, compared with 3.6% at 31 December 2016.

EPRA NNNAV stood at €3,729 million or €80.1 per share at 31 December 2017, an increase of 21.0% compared to €66.2 per share at 31 December 2016.

Dividend

At the Annual General Meeting to be held on 20 April 2018, the Board of Directors will recommend paying a dividend of €2.30 per share.

Alternative Performance Indicators (APIs)

API EPRA earnings

€ millions   2017   2016
Attributable net profit   685.3   504.1
Less:
Profit (loss) on asset disposals (80.3) -
Non-recurring disposal costs 3.0 -
Fair value adjustments to investment properties (635.1) (438.0)
Fair value adjustments to financial instruments, discounting adjustments to debt and related costs (0.6) 2.1
Tax on the above items 33.3 (11.6)
Non-controlling interests in the above items   96.8   44.3
EPRA earnings   102.4   100.9

API EPRA NNNAV

€ millions   31/12/2017   31/12/2016
Attributable equity   3,763   3,123
Treasury shares 11 14
Unrealised capital gains 17 16
Fair value adjustments to fixed rate debt   (62)   (71)
EPRA NNNAV   3,729   3,082

API Net debt

€ millions   31/12/2017   31/12/2016
Long-term borrowings and derivative instruments   1,661   1,620
Short-term borrowings and other interest-bearing debt   36   389
Debt in the consolidated statement of financial position   1,697   2,009
Less:
Current account advances (liabilities) (56) (63)
Accrued interest and deferred recognition of debt arranging fees 6 6
Cash and cash equivalents   (16)   (20)
Net debt   1,631   1,931

More Information is available at www.fonciere-lyonnaise.com

About SFL

Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €6.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.

Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA

S&P rating: BBB+ stable outlook

www.fonciere-lyonnaise.com

Contact information

SFL
Thomas Fareng, Phone +33 (0)1 42 97 27 00
t.fareng@fonciere-lyonnaise.com
or
Evidence
Grégoire Silly, Phone +33 (0)1 45 63 49 73
gregoire.silly@evidenceparis.fr

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third